Literature DB >> 22266263

Applications of supercritical fluids to enhance the dissolution behaviors of Furosemide by generation of microparticles and solid dispersions.

Nicola De Zordi1, Mariarosa Moneghini, Ireneo Kikic, Mario Grassi, Antonio Esau Del Rio Castillo, Dario Solinas, Michael B Bolger.   

Abstract

The 'classical' loop diuretic drug Furosemide has been used as a model compound to investigate the possibility of enhancing the dissolution rate of poorly water-soluble drugs using supercritical anti-solvent techniques (SASs). In the present study we report upon the in vitro bioavailability improvement of Furosemide through particle size reduction as well as formation of solid dispersions (SDs) using the hydrophilic polymer Crospovidone. Supercritical carbon dioxide was used as the processing medium for these experiments. In order to successfully design a CO(2) antisolvent process, preliminary studies of Furosemide microparticles generation were conducted using Peng Robinson's Equation of State. These preliminary studies indicated using acetone as a solvent with pressures of 100 and 200bar and a temperature of 313K would yield optimum results. These operative conditions were then adopted for the SDs. Micronization by means of SAS at 200bar resulted in a significant reduction of crystallites, particle size, as well as improved dissolution rate in comparison with untreated drug. Furosemide recrystallized by SAS at 100bar and using traditional solvent evaporation. Moreover, changes in polymorphic form were observed in the 200bar samples. The physicochemical characterization of Furosemide:crospovidone SDs (1:1 and 1:2 w/w, respectively) generated by SAS revealed the presence of the drug amorphously dispersed in the 1:2 w/w sample at 100bar still remaining stable after 6months. This sample exhibits the best in vitro dissolution performance in the simulated gastric fluid (pH 1.2), in comparison with the same SD obtained by traditional method. No interactions between drug and polymer were observed. These results, together with the presence of the selected carrier, confirm that the use of Supercritical fluids antisolvent technology is a valid mean to increase the dissolution rate of poorly soluble drugs. Theoretical in vivo-in vitro relation was predicted by means of a pharmacokinetics mathematical model.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22266263     DOI: 10.1016/j.ejpb.2012.01.002

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  5 in total

1.  Development and characterization of solid dispersion for dissolution improvement of furosemide by cogrinding method.

Authors:  Mohammad Reza Siahi-Shadbad; Saeed Ghanbarzadeh; Mohammad Barzegar-Jalali; Hadi Valizadeh; Alireza Taherpoor; Ghobad Mohammadi; Azim Barzegar-Jalali; Khosro Adibkia
Journal:  Adv Pharm Bull       Date:  2014-08-10

Review 2.  Bioavailability Enhancement of Poorly Water-Soluble Drugs via Nanocomposites: Formulation⁻Processing Aspects and Challenges.

Authors:  Anagha Bhakay; Mahbubur Rahman; Rajesh N Dave; Ecevit Bilgili
Journal:  Pharmaceutics       Date:  2018-07-08       Impact factor: 6.321

3.  Development and characterization of solid dispersion of piroxicam for improvement of dissolution rate using hydrophilic carriers.

Authors:  Mohammad Barzegar-Jalali; Saeed Ghanbarzadeh; Khosro Adibkia; Hadi Valizadeh; Siamak Bibak; Ghobad Mohammadi; Mohammad Reza Siahi-Shadbad
Journal:  Bioimpacts       Date:  2014-08-31

Review 4.  Supercritical Fluid Technology: An Emphasis on Drug Delivery and Related Biomedical Applications.

Authors:  Ranjith Kumar Kankala; Yu Shrike Zhang; Shi-Bin Wang; Chia-Hung Lee; Ai-Zheng Chen
Journal:  Adv Healthc Mater       Date:  2017-07-28       Impact factor: 9.933

5.  Influence of Aqueous Solubility-Enhancing Excipients on the Microstructural Characteristics of Furosemide-Loaded Electrospun Nanofibers.

Authors:  Andrea Kovács; Adrienn Kazsoki; Balázs Démuth; Bernadett Szirányi; János Madarász; Károly Süvegh; Romána Zelkó
Journal:  Pharmaceutics       Date:  2020-04-23       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.